Anticoagulation with Edoxaban in COVID-19 patients
- Journal of Cardiology & Current Research
Giovanni Fazio,1 Staffiere Elio,2 Luigi Gianturco,3 Lara Di Diodoro,4 Sergio Pipitone,4 Emanuele Verghi,5 Paolo Colonna,6 Maurizio Volterrani,7 Gabriele Catena4
The SARS-CoV-2 infection causes a thromboembolism and even disseminated intravascular coagulation (DIC). We enrolled 884 consecutive patients receiving edoxaban and with a positive Sars-Cov-2 swab, that were enrolled in our retrospective observational study and recruited in 7 Italian regions. About 884 positives patients the mean age was 71years, with a male/female ratio was 0,8%.87 (9,8%) were hospitalized while the remaining 797 (91,2%) were home isolated. From 87 hospitalized patients only 9 (1, 1%) were in the intensive care unit. Only 2 (0,3%) patients died. Albeit the limitations of the retrospective evaluation and the epidemiological analysis, there seems to emerge that treatment with edoxaban protects from the development of complications in patients with COVID-19.
SARS-Cov-2, edoxaban, lethality, mortality, hospitalization, intensive care, DIC, disseminated intravascular coagulation, NVAF, non-valvular atrial fibrillation, VTE, venous thromboembolism